Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status

Yu,Da‑Ping; Dong,Yu‑Jie; Zhang,Hai‑Qing; Wang,Jing‑Hui; Qu,Yang; Zhou,Li‑Juan; Su,Dan; Zhang,Li‑Li; Zhao,Dan; Cai,Yi‑Ran

doi:10.3892/br.2014.261

Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status

Authors:
- Da‑Ping Yu
- Yu‑Jie Dong
- Hai‑Qing Zhang
- Jing‑Hui Wang
- Yang Qu
- Li‑Juan Zhou
- Dan Su
- Li‑Li Zhang
- Dan Zhao
- Yi‑Ran Cai
View Affiliations

Affiliations: Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, P.R. China, Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, P.R. China, Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, P.R. China
Published online on: March 20, 2014 https://doi.org/10.3892/br.2014.261
Pages: 481-489

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small‑cell lung cancer (NSCLC) is the most common cause of cancer‑related mortality. Adenocarcinoma (AC) is the predominant histological type of NSCLC; however, AC consists of several subtypes. It has not yet been determined whether there is a correlation of CRKL and AXL expression with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene status in lung AC. We assayed exons 18 through 21 of the EGFR gene by direct sequencing; ALK rearrangement and the expression of CRKL and AXL were detected by immunostaining. A total of 212 cases of AC were included in this study, diagnosed using the novel classification system established by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society in 2011, including 69 acinar ACs, 17 lepidic predominant ACs (LPAs), 63 papillary, 14 mucinous, 17 micropapillary and 32 solid ACs. Of the 212 cases, 101 harbored EGFR mutations. The most common subtypes carrying delK745‑S753 were papillary and acinar ACs. ALK rearrangement was found in 23 cases (11%) of lung ACs. Acinar and solid ACs were the most frequent subtypes with ALK aberrance, particularly in acinar ACs with cribriform structure (4/5 cases, 80%). The expression of CRKL was significantly different among the AC subtypes (P=0.01), with the highest and lowest expression levels of CRKL protein in papillary ACs and LPAs, respectively (P<0.05). AXL expression was also significantly different among the AC subtypes (P=0.002) and was correlated with lymph node infiltration in acinar ACs. ACs with EGFR mutations exhibited high levels of AXL protein expression compared to those without mutations (P<0.001). Acinar AC with cribriform structure is a distinct subtype that frequently harbors ALK rearrangement. The activation of AXL may be one of the factors contributing to the invasion of acinar and micropapillary ACs.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Boyle P and Levin B: World Cancer Report 2008. IARC Scientific Publications; Lyon: 2008
3	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P: Cancer Incidence in Five Continents. IX. IARC Scientific Publications; Lyon: 2007
4	Terasaki H, Niki T, Matsuno Y, et al: Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 27:937–951. 2003. View Article : Google Scholar
5	Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar
6	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: 2004
7	Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E: Histological Typing of Lung and Pleural Tumors. 3rd edition. Springer; Berlin: 1999, View Article : Google Scholar
8	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
9	Riely GJ, Politi KA, Miller VA and Pao W: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 12:7232–7241. 2006. View Article : Google Scholar : PubMed/NCBI
10	Sakai K, Arao T, Shimoyama T, et al: Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. FASEB J. 20:311–313. 2006.PubMed/NCBI
11	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gandhi L and Janne PA: Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res. 18:3737–3742. 2012. View Article : Google Scholar : PubMed/NCBI
14	Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 16:1561–1571. 2010. View Article : Google Scholar : PubMed/NCBI
16	ten Hoeve J, Kaartinen V, Fioretos T, et al: Cellular interactions of CRKL and SH2-SH3 adaptor protein. Cancer Res. 54:2563–2567. 1994.PubMed/NCBI
17	Senechal K, Halpern J and Sawyers CL: The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem. 271:23255–23261. 1996. View Article : Google Scholar : PubMed/NCBI
18	Hafizi S and Dahlback B: Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 17:295–304. 2006. View Article : Google Scholar : PubMed/NCBI
19	Goruppi S, Ruaro E, Varnum B and Schneider C: Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol. 17:4442–4453. 1997.PubMed/NCBI
20	Hector A, Montgomery EA, Karikari C, et al: The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther. 10:1009–1018. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
22	Paccez JD, Vasques GJ, Correa RG, et al: The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene. 32:689–698. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cai YR, Zhang HQ, Qu Y, et al: Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep. 26:877–885. 2011.PubMed/NCBI
24	Lee HJ, Xu X, Choe G, et al: Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer. 68:375–382. 2010. View Article : Google Scholar
25	Motoi N, Szoke J, Riely GJ, et al: Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 32:810–827. 2008. View Article : Google Scholar
26	Sica G, Yoshizawa A, Sima CS, et al: A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 34:1155–1162. 2010. View Article : Google Scholar : PubMed/NCBI
27	De Oliveira Duarte Achcar R, Nikiforova MN and Yousem SA: Micropapillary lung adenocarcinoma: EGFR, K-ras and BRAF mutational profile. Am J Clin Pathol. 131:694–700. 2009.PubMed/NCBI
28	Kim YH, Ishii G, Goto K, et al: Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res. 10:7311–7317. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
30	Okudela K, Woo T, Mitsui H, et al: Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease. Int J Clin Exp Pathol. 3:348–366. 2010.
31	Amin MB, Tamboli P, Merchant SH, et al: Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 26:358–364. 2002. View Article : Google Scholar : PubMed/NCBI
32	Tsutsumida H, Nomoto M, Goto M, et al: A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol. 20:638–647. 2007. View Article : Google Scholar : PubMed/NCBI
33	Yoshizawa A, Motoi N, Riely GJ, et al: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 24:653–664. 2011. View Article : Google Scholar
34	Cheung HW, Du J, Boehm JS, et al: Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 1:608–625. 2011. View Article : Google Scholar : PubMed/NCBI
35	Finberg KE, Sequist LV, Joshi VA, et al: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 9:320–326. 2007. View Article : Google Scholar : PubMed/NCBI
36	Suda K, Murakami I, Katayama T, et al: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI
37	Zhang X, Gureasko J, Shen K, Cole PA and Kuriyan J: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 125:1137–1149. 2006. View Article : Google Scholar : PubMed/NCBI
38	Takeuchi K, Choi YL, Togashi Y, et al: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
39	Boland JM, Erdogan S, Vasmatzis G, et al: Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 40:1152–1158. 2009. View Article : Google Scholar : PubMed/NCBI
40	Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
41	Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
42	O’Bryan JP, Frye RA, Cogswell PC, et al: Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 11:5016–5031. 1991.PubMed/NCBI
43	Neubauer A, O’Bryan JP, Fiebeler A, Schmidt C, Huhn D and Liu ET: Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. Semin Hematol. 30(3 Suppl 3)34:1993
44	Lee HY, Han J, Lee KS, et al: Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer. 66:379–385. 2009. View Article : Google Scholar : PubMed/NCBI
45	Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S and Ochiai A: Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 29:179–188. 2000. View Article : Google Scholar : PubMed/NCBI
46	Lin DM, Ma Y, Zheng S, Liu XY, Zou SM and Wei WQ: Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol. 21:627–632. 2006.PubMed/NCBI